Literature DB >> 31515714

Prevalence and Predictors of Symptoms of Depression Among Individuals Seeking Treatment from Australian Drug and Alcohol Outpatient Clinics.

Breanne Hobden1,2,3,4, Mariko Carey5,6,7, Jamie Bryant5,6,7, Rob Sanson-Fisher5,6,7, Christopher Oldmeadow8,9.   

Abstract

This study examined the prevalence of and sociodemographic characteristics associated with elevated symptoms of depression among clients seeking alcohol or other drug (AOD) treatment. Consenting clients attending two AOD outpatient clinics answered demographics, treatment questions and the Patient Health Questionnaire to assess depressive symptoms. Counts and percentages were calculated to determine the prevalence of elevated depressive symptoms. Logistic regression was used to model the odds of having elevated depressive symptoms for client demographics. Of the 203 clients who completed the survey (87% consent rate), 55% (n = 111) demonstrated elevated depressive symptoms. Females were twice as likely to experience elevated symptoms of depression compared to males (OR 2.07; 95% CI 1.05, 4.08; P = 0.037). The high rates of elevated depressive symptoms among individuals seeking AOD treatment highlight the importance of ongoing research to provide effective treatments for this comorbidity. Routine screening and clear treatment pathways may assist with providing high quality care.

Entities:  

Keywords:  Mental health; Mood disorders; Population characteristics; Substance-related disorders

Mesh:

Year:  2019        PMID: 31515714     DOI: 10.1007/s10597-019-00451-3

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  32 in total

1.  Prevalence and predictors of psychopathology among opioid users.

Authors:  S Darke; A Wodak; W Hall; N Heather; J Ward
Journal:  Br J Addict       Date:  1992-05

2.  Screening for mental disorder comorbidity in Australian alcohol and other drug residential treatment settings.

Authors:  Kane Saxon Mortlock; Frank P Deane; Trevor Patrick Crowe
Journal:  J Subst Abuse Treat       Date:  2011-02-25

Review 3.  A systematic review of the prevalence of comorbid mental health disorders in people presenting for substance use treatment in Australia.

Authors:  Rosemary E F Kingston; Christina Marel; Katherine L Mills
Journal:  Drug Alcohol Rev       Date:  2016-10-27

Review 4.  Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

Authors:  Edward V Nunes; Frances R Levin
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

5.  Suicidal thoughts and behaviours among Australian adults: findings from the 2007 National Survey of Mental Health and Wellbeing.

Authors:  Amy K Johnston; Jane E Pirkis; Philip M Burgess
Journal:  Aust N Z J Psychiatry       Date:  2009-07       Impact factor: 5.744

6.  Comorbidity in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing.

Authors:  Maree Teesson; Tim Slade; Katherine Mills
Journal:  Aust N Z J Psychiatry       Date:  2009-07       Impact factor: 5.744

7.  Service use for mental health problems: findings from the 2007 National Survey of Mental Health and Wellbeing.

Authors:  Philip M Burgess; Jane E Pirkis; Tim N Slade; Amy K Johnston; Graham N Meadows; Jane M Gunn
Journal:  Aust N Z J Psychiatry       Date:  2009-07       Impact factor: 5.744

8.  Comparing the BDI-II and the PHQ-9 with outpatient substance abusers.

Authors:  Mariam Dum; Jason Pickren; Linda Carter Sobell; Mark B Sobell
Journal:  Addict Behav       Date:  2007-09-29       Impact factor: 3.913

9.  The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication.

Authors:  Lisa A Martin; Harold W Neighbors; Derek M Griffith
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

10.  Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010.

Authors:  Alize J Ferrari; Fiona J Charlson; Rosana E Norman; Scott B Patten; Greg Freedman; Christopher J L Murray; Theo Vos; Harvey A Whiteford
Journal:  PLoS Med       Date:  2013-11-05       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.